Clinical trial
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil.
NCT04948411 is registered in ClinicalTrials.gov with Latin American Cooperative Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil.
- Lead sponsor
- Latin American Cooperative Oncology Group
- Phase
- Observational
- Overall status
- Completed
- Start date
- September 30, 2021
- Completion date
- February 1, 2023
- Enrollment
- 33 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.